Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Immuneering Corp

IMRX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$5.06

▼ -2.69%

Market Cap $327.37M · Vol 152.39K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$327.37M

Small Cap

Div Yield

N/A

EPS Growth

+10.54%

YoY

RSI (14)

69.34

Momentum

Beta

0.42

vs Market

52W High

$10.08

49.80% below

52W Low

$3.00

68.67% above

Volume

152.39K

Avg 238.19K

P/B

1.95

Price-to-book

ROE

N/A

Return on equity

Free Float

86.08%

Public shares

Shariah Compliance8 STANDARDS

✗ Immuneering Corp (IMRX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IMRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+12.20%

-2.88%

-1.56%

+2.64%

YTD

-23.10%

+66.45%

-46.11%

-82.32%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-56,024,900.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-39.36% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.95
P/FCF	N/A
EPS Growth	+10.54%
Outstanding Shares	64.70M

Technical Indicators

50-Day SMA	$4.60
200-Day SMA	$5.37
RSI (14)	69.34
Beta	0.42
52-Week High	$10.08
52-Week Low	$3.00

Volume Today	152.39K
Avg Daily Volume (30D)	238.19K
Relative Volume	0.64x
Volatility (10D)	41.78
Volatility (30D)	58.83
Free Float	86.08%

Analyst Consensus

BUY

Current Price $5.06

Mean Target $17.57

52W Low$3.00 52W High$10.08

Current

Target

$3.00 $10.08

Current Analyst target

+247.26% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG009QXJQV7

ISINUS45254E1073

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.